Future

Billion

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">Eli Lilly and Company (NYSE: <a href="https://tokenist.com/tag/eli-lilly/" rel="noopener noreferrer nofollow" class="deco-link">LLY</a>), a global healthcare leader, has released its <a aria-label="financial results (opens in a new tab)" href="https://investor.lilly.com/financial-information/quarterly-results" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">financial results</a> for the fourth quarter of 2023, demonstrating a remarkable period of growth and strategic advancements.</p>
<p>Eli Lilly’s financial performance in the fourth quarter of 2023 was nothing short of impressive. The company reported a 28% increase in revenue compared to the same quarter last year, reaching $9.35 billion. <br><br>Importantly, this growth was driven by a significant contribution from new products, including Mounjaro and Zepbound, which saw revenue soar by $2.19 billion to $2.49 billion. Growth products like Verzenio and Jardiance also performed well, contributing to a 9% increase in their revenue stream to $5.27 billion. The company’s earnings per share (EPS) on a reported basis grew by 13% to $2.42, and on a non-GAAP basis, it increased by 19% to $2.49, both inclusive of $0.62 of acquired IPR&amp;D charges.</p>
<h3 id="eli-lilly-smashes-lofty-expectations-in-q4">Eli Lilly Smashes Lofty Expectations in Q4</h3>
<p>When compared to the expected earnings per share (<a href="https://tokenist.com/investing/fundamental-analysis-stocks/" rel="noopener noreferrer nofollow" class="deco-link">EPS</a>) of $2.31 and revenue of $8.95 billion for the quarter, Eli Lilly’s actual results exceeded market expectations. The company’s EPS of $2.49 on a non-GAAP basis surpassed the forecast, highlighting efficient operational management and a strong product portfolio. Similarly, the revenue of $9.35 billion indicated a robust demand for Lilly’s products, particularly the new and growth products, which have been critical drivers of this quarter’s performance. This outperformance reflects the company’s ability to navigate the pharmaceutical landscape adeptly, capitalizing on its innovative product lineup and strategic market positioning.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking digital asset story.</a></p>
 </div>
</div>
<h3 id="guidance-for-the-future">Guidance for the Future</h3>
<p>Looking ahead, Eli Lilly provided optimistic guidance for 2024, projecting revenue in the range of $40.4 billion to $41.6 billion and EPS between $11.80 to $12.30 on a reported basis, with non-GAAP EPS expected to be between $12.20 to $12.70. This guidance anticipates continued revenue growth, largely driven by the new product lineup, albeit partially offset by expected declines in Trulicity sales. The company also plans to further invest in research and development, as well as in marketing and administrative expenses, to support the growth of its recently launched and upcoming products. Such forward-looking statements reflect Lilly’s confidence in its pipeline and its strategic focus on addressing unmet medical needs.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/eli-lilly-lly-surpasses-expectations-with-9-35-billion-in-q4-revenue/">Eli Lilly (LLY) Surpasses Expectations with $9.35 Billion in Q4 Revenue</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Eli Lilly (LLY) Surpasses Expectations with $9.35 Billion in Q4 Revenue

목차

Tokenist

2024년 2월 6일에 게재된 다른 기사

FTT Coin’s Value Tumbles as FTX Exchange Faces Terminal Closure

ADA and AVAX Begin Recovery, But Experts Back NuggetRush (NUGX) To Outperform Them

There's No Trust Between Colleagues. You Can Lose $25 Million On The Call!

Rollbit Investors Turn to Scorpion Casino for the Next 100x Opportunity – Here’s Why

Top Analyst Unveils 2024 Bull Run Picks, Allocates 75% of Portfolio to Two Cryptocurrencies Set T...

Solana still at a standstill: The ambition to compete with Ethereum falters!

무료 뉴스레터에 가입하여 매일 최신 암호화폐 소식을 받아보세요!